HUP0001183A3 - Pyrrolothiazine and pyrrolothiazepine derivatives, process for their preparation and pharmaceutical compositions containing them - Google Patents

Pyrrolothiazine and pyrrolothiazepine derivatives, process for their preparation and pharmaceutical compositions containing them

Info

Publication number
HUP0001183A3
HUP0001183A3 HU0001183A HUP0001183A HUP0001183A3 HU P0001183 A3 HUP0001183 A3 HU P0001183A3 HU 0001183 A HU0001183 A HU 0001183A HU P0001183 A HUP0001183 A HU P0001183A HU P0001183 A3 HUP0001183 A3 HU P0001183A3
Authority
HU
Hungary
Prior art keywords
pyrrolothiazine
pyrrolothiazepine
derivatives
preparation
pharmaceutical compositions
Prior art date
Application number
HU0001183A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Daiichi Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Asubio Pharma Co Ltd filed Critical Daiichi Asubio Pharma Co Ltd
Publication of HUP0001183A2 publication Critical patent/HUP0001183A2/hu
Publication of HUP0001183A3 publication Critical patent/HUP0001183A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HU0001183A 1997-12-26 1998-12-25 Pyrrolothiazine and pyrrolothiazepine derivatives, process for their preparation and pharmaceutical compositions containing them HUP0001183A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9366757A JPH11193290A (ja) 1997-12-26 1997-12-26 ピロールスルホンアミド系化合物
PCT/JP1998/005955 WO1999033841A2 (en) 1997-12-26 1998-12-25 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action

Publications (2)

Publication Number Publication Date
HUP0001183A2 HUP0001183A2 (hu) 2000-10-28
HUP0001183A3 true HUP0001183A3 (en) 2002-12-28

Family

ID=18487596

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001183A HUP0001183A3 (en) 1997-12-26 1998-12-25 Pyrrolothiazine and pyrrolothiazepine derivatives, process for their preparation and pharmaceutical compositions containing them

Country Status (9)

Country Link
US (3) US6331623B1 (enExample)
EP (1) EP0970089A2 (enExample)
JP (1) JPH11193290A (enExample)
KR (1) KR20000075642A (enExample)
CN (2) CN1131870C (enExample)
AU (1) AU752510B2 (enExample)
CA (1) CA2282815A1 (enExample)
HU (1) HUP0001183A3 (enExample)
WO (1) WO1999033841A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11193289A (ja) * 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド誘導体
JPH11193290A (ja) * 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド系化合物
ES2919779T3 (es) 2017-06-20 2022-07-28 Imbria Pharmaceuticals Inc Derivado de 1-[(2,3,4-trimetoxifenil)metil]-piperazina, composiciones del mismo y métodos para aumentar la eficiencia del metabolismo cardíaco
US12318382B2 (en) 2018-10-17 2025-06-03 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3198117B2 (ja) 1990-02-07 2001-08-13 サントリー株式会社 ピロロアゼピン誘導体
FR2675802B1 (fr) * 1991-04-26 1993-12-24 Rhone Poulenc Rorer Sa Antiserotonines, leur preparation et les medicaments les contenant.
US5399557A (en) 1991-08-07 1995-03-21 Suntory Limited Pyrroloazepine compound
ATE236162T1 (de) 1991-08-07 2003-04-15 Suntory Ltd Pyrroloazepinderivate
WO1995018117A1 (en) * 1993-12-24 1995-07-06 Suntory Limited Benzothiazine derivative
CA2189297C (en) 1995-11-02 2004-09-21 Masahiro Imoto Process for preparing 1-substituted pyrrole-3-carboxylic acid derivatives
ATE216388T1 (de) * 1995-12-01 2002-05-15 Suntory Ltd Pyrroloazepin-derivate
JPH10251258A (ja) 1997-03-14 1998-09-22 Suntory Ltd ピロロアゼピン系化合物
JPH11193289A (ja) 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド誘導体
JPH11193290A (ja) * 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド系化合物
IL139064A0 (en) 1999-02-17 2001-11-25 Suntory Ltd Intermittent claudication therapeutic drugs comprising pyrroloazepines

Also Published As

Publication number Publication date
EP0970089A2 (en) 2000-01-12
AU1690799A (en) 1999-07-19
HUP0001183A2 (hu) 2000-10-28
WO1999033841B1 (en) 2001-05-25
US20030229070A1 (en) 2003-12-11
CA2282815A1 (en) 1999-07-08
CN1261366A (zh) 2000-07-26
AU752510B2 (en) 2002-09-19
WO1999033841A3 (en) 1999-09-02
WO1999033841A2 (en) 1999-07-08
JPH11193290A (ja) 1999-07-21
US20020137928A1 (en) 2002-09-26
US6331623B1 (en) 2001-12-18
CN1495163A (zh) 2004-05-12
KR20000075642A (ko) 2000-12-26
CN1193014C (zh) 2005-03-16
US6743913B2 (en) 2004-06-01
US6583296B2 (en) 2003-06-24
CN1131870C (zh) 2003-12-24

Similar Documents

Publication Publication Date Title
HUP9700358A3 (en) New oxazolidinon derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0000721A3 (en) Gemcitabine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0100431A3 (en) Adamantana derivatives, pharmaceutical compositions comprising them and process for preparing them
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
HUP0001555A3 (en) Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
HUP0004024A3 (en) Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
HUP9904680A3 (en) Thienopyrimidine derivatives, pharmaceutical compositions containing them and process for their preparation
HUP0203316A3 (en) Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP9801044A3 (en) Sulfonylamino-carboxylic acid derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP9602122A2 (en) Camptothecin derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP9801045A3 (en) Sulfonyl-amino-carboxylic acid derivatives, use thereof, pharmaceutical compositions containing them and process for their preparation
HUP9802422A3 (en) Substituted isoquinoline-3-carboxamide derivatives, process for producing them and pharmaceutical compositions containing them
HUP9900974A3 (en) Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
HUP0202731A3 (en) O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0201516A3 (en) 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0201753A3 (en) Pyridopyranoazepine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP9602635A3 (en) 4-aciloxy-benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0100488A3 (en) Thienopyrimidines, process for their preparation and pharmaceutical compositions containing them
HUP0203184A3 (en) Isoxazolecarboxamide derivatives, process for their preparation and pharmaceutical compositions containing them
ZA983997B (en) Triazole derivatives, process for their preparation and pharmaceutical compositions containing them.
HUP0002300A3 (en) Quinoline-4-carboxamide derivatives, process for producing them, pharmaceutical compositions containing them and their use
HUP0003577A3 (en) Tetrahydro gamma-carbolines, process for their preparation, their use and pharmaceutical compositions containing them
HUP9801386A3 (en) Indazolecarboxamide derivatives, preparation thereof and pharmaceutical compositions containing them
GB9617893D0 (en) New pharmaceutical derivatives, process for obtaining them and pharmaceutical compositions containing them
HUP0101234A3 (en) Betha-carboline derivatives, process for their preparation and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: ASUBIO PHARMA CO., LTD., JP

Free format text: FORMER OWNER(S): DAIICHI ASUBIO PHARMA CO., LTD., JP; DAIICHI SUNTORY PHARMA CO., LTD., JP; SUNTORY LIMITED, JP

FD9A Lapse of provisional protection due to non-payment of fees